Announced details
Cancer treatment and malignant tumors. The target patients are patients with advanced, metastatic, recurrent or refractory malignant tumors.
The company will present its research findings at the AACR Annual Meeting. Capital, personnel and business relationships are Not disclosed.
American Association for Cancer Research (AACR). The venue stated in the source is San Diego, California, U.S. Other details are Not disclosed.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
American Association for Cancer Research (AACR) Annual Meeting, Abstracts Online (https://www.abstractsonline.com/pp8/#!/21436/presentation/3431)
| Item | Details |
|---|---|
| Names of Products / Services Covered | monzosertib, AS-0141 |
| Counterparty | American Association for Cancer Research (AACR) |
| Counterparty overview | American Association for Cancer Research (AACR). The venue stated in the source is San Diego, California, U.S. Other details are Not disclosed. |
| Relationship with the Company | The company will present its research findings at the AACR Annual Meeting. Capital, personnel and business relationships are Not disclosed. |
| Launch date | 20 April 2026 (scheduled; presentation date) |
| Applicable area | Cancer treatment and malignant tumors. The target patients are patients with advanced, metastatic, recurrent or refractory malignant tumors. |
| Source | American Association for Cancer Research (AACR) Annual Meeting, Abstracts Online (https://www.abstractsonline.com/pp8/#!/21436/presentation/3431) |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To present new findings on the mechanism of cell death induced by monzosertib, based on analyses using cancer cell lines, at the AACR Annual Meeting.